These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 30700860)
1. What is 'LDL cholesterol'? Holmes MV; Ala-Korpela M Nat Rev Cardiol; 2019 Apr; 16(4):197-198. PubMed ID: 30700860 [No Abstract] [Full Text] [Related]
2. Dyslipidaemia: Is CETP inhibition a viable therapeutic strategy? Fernández-Ruiz I Nat Rev Cardiol; 2017 Jul; 14(7):382-383. PubMed ID: 28569268 [No Abstract] [Full Text] [Related]
3. Dyslipidaemias in 2017: Atherogenic lipoproteins as treatment targets. Catapano AL Nat Rev Cardiol; 2018 Jan; 15(2):75-76. PubMed ID: 29336436 [No Abstract] [Full Text] [Related]
4. Editorial: collecting new external evidence for cholesterol management. Streja D Curr Opin Endocrinol Diabetes Obes; 2016 Apr; 23(2):121-3. PubMed ID: 26863279 [No Abstract] [Full Text] [Related]
5. Effect of Evolocumab on Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies. Toth PP; Jones SR; Monsalvo ML; Elliott-Davey M; López JAG; Banach M J Am Heart Assoc; 2020 Mar; 9(5):e014129. PubMed ID: 32114889 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial. Taskinen MR; Del Prato S; Bujas-Bobanovic M; Louie MJ; Letierce A; Thompson D; Colhoun HM Atherosclerosis; 2018 Sep; 276():124-130. PubMed ID: 30059843 [TBL] [Abstract][Full Text] [Related]
7. Success, Failure, and Transparency in Biomarker-Based Drug Development: A Case Study of Cholesteryl Ester Transfer Protein Inhibitors. Hey SP; Franklin JM; Avorn J; Kesselheim AS Circ Cardiovasc Qual Outcomes; 2017 Jun; 10(6):. PubMed ID: 28611186 [TBL] [Abstract][Full Text] [Related]
8. New joint consensus initiative on quantifying atherogenic lipoproteins. Stock JK Atherosclerosis; 2018 Dec; 279():97-99. PubMed ID: 30318139 [No Abstract] [Full Text] [Related]
10. Dyslipidaemia in 2015: Advances in treatment of dyslipidaemia. Grundy SM Nat Rev Cardiol; 2016 Feb; 13(2):74-5. PubMed ID: 26763537 [No Abstract] [Full Text] [Related]
11. Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world study. Hollstein T; Vogt A; Grenkowitz T; Stojakovic T; März W; Laufs U; Bölükbasi B; Steinhagen-Thiessen E; Scharnagl H; Kassner U Vascul Pharmacol; 2019 May; 116():8-15. PubMed ID: 30910670 [TBL] [Abstract][Full Text] [Related]
12. Journey through cholesteryl ester transfer protein inhibition: from bench to bedside. Karalis I; Rensen PC; Jukema JW Circ Cardiovasc Qual Outcomes; 2013 May; 6(3):360-6. PubMed ID: 23674310 [No Abstract] [Full Text] [Related]
13. Counterpoint: Low-Density Lipoprotein Cholesterol Targets Are Not Needed in Lipid Treatment Guidelines. Robinson JG; Ray K Arterioscler Thromb Vasc Biol; 2016 Apr; 36(4):586-90. PubMed ID: 26988588 [TBL] [Abstract][Full Text] [Related]
14. Lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in Japanese patients with dyslipidemia. Teramoto T; Daida H; Ikewaki K; Arai H; Maeda Y; Nakagomi M; Shirakawa M; Watanabe Y; Kakikawa T; Numaguchi H; Johnson-Levonas AO; Blaustein RO Atherosclerosis; 2017 Jun; 261():69-77. PubMed ID: 28478132 [TBL] [Abstract][Full Text] [Related]